Cynthia Collins

Ms. Cynthia L.
Collins is an Independent Director at Codexis, Inc., an Independent Non-Executive Director at MaxCyte, Inc. and an Independent Director at DermTech, Inc. She is on the Board of Directors at Codexis, Inc., MaxCyte, Inc., The Charles Stark Draper Laboratory, Inc., DermTech, Inc., Cavidi AB, Alanis Therapeutics, Inc., Analytical Life Science & Diagnostics Association and Panavance Therapeutics, Inc. Ms. Collins was previously employed as an Executive Chairman & Chief Executive Officer by Nutcracker Therapeutics, Inc., an Independent Director by Certara, Inc., an Independent Director by Poseida Therapeutics, Inc., a President & Chief Executive Officer by Editas Medicine, Inc., a Chief Executive Officer by Human Longevity, Inc., a Chief Executive Officer by Clarient, Inc., a Chief Executive Officer & GM-Cell Therapy Business by GE Healthcare, Inc., a President, Chief Executive Officer & Director by GenVec, Inc., a Group Vice President-Cellular Analysis Business by Beckman Coulter, Inc., a President & Chief Executive Officer by Sequoia Pharmaceuticals, Inc., a President by Clinical Micro Sensors, Inc., and a President-Global Oncology by Baxter Healthcare SA. She also served on the board at Biocare Medical LLC, DermTech, Inc. /Old/, Triumvira Immunologics, Inc., Provista Diagnostics, Inc., Alliance for Regenerative Medicine, Arm Foundation, Biohealth Innovation, Inc., GMJ KK and Triumvira Immunologics USA, Inc. She received her undergraduate degree from the University of Illinois At Urbana–Champaign and an MBA from The University of Chicago Booth School of Business.